echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Tisagenlecleucel is effective and safe in adult patients with relapsed/refractory primary CNS lymphoma

    Tisagenlecleucel is effective and safe in adult patients with relapsed/refractory primary CNS lymphoma

    • Last Update: 2022-04-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma (NHL) confined to the brain, pia mater, eye, and/or spinal cord, although it is pathologically associated with systemic large B-cell lymphoma.
    Neoplasms (LBCL) were similar, but newly diagnosed PCNSL had a worse prognosis than other NHL subtypes, with 5-year and 10-year overall survival (OS) rates of 29.
    3% and 21.
    6%, respectively
    .

    In general, patients with relapsed and refractory (R/R) PCNSL have a poor prognosis with a median OS of about 4 months and lack of effective salvage therapy
    .

    Real-world data from the International Center for Blood and Bone Marrow Transplantation Study (CIBMTR) demonstrate a lower incidence of severe immune effector cell-associated neurotoxicity syndrome (ICANS) in systemic lymphoma with Tisagenlecleucel, and results from a previous retrospective study demonstrating Tisagenlecleucel Safety and efficacy in secondary central nervous system lymphoma
    .

    Therefore, we conducted a prospective phase I/II study to evaluate the safety and efficacy of Tisagenlecleucel in patients with highly refractory PCNSL
    .

    Research Methods This phase I/II clinical study evaluated the efficacy and safety of Tisagenlecleucel in adult patients with R/R PCNSL
    .

    The Phase I study was designed to evaluate treatment-related toxicity in a PCNSL patient population at FDA-approved CAR-T doses (0.
    6-6.
    0 x 108 CAR+ T cells) in 6 patients, and an additional 6 patients were treated as part of a Phase II extension study
    .

    Patients included in the study must be 18 years of age or older with disease progression or relapse after high-dose methotrexate (HD-MTX)-based systemic therapy
    .

    Elderly (>60 years of age) patients were also eligible to participate in the study due to poor prognosis and if elderly patients were unable to tolerate first-line therapy due to grade 3+ renal or hepatic impairment
    .

    All patients required a confirmed diagnosis of PCNSL and no systemic disease
    .

    The patient received a lymphodepleting chemotherapy (LDC) regimen of fludarabine (25 mg/m2/d) and cyclophosphamide (250 mg/m2/d) on days -5, -4, and -3
    .

    All patients received seizure prophylaxis
    .

    In the absence of cytokine release syndrome (CRS)/ICANS, initiation of growth factor supportive therapy on day +7 was permitted
    .

    All patients required repeat baseline assessments before LDC and after any subsequent bridging therapy
    .

    The primary endpoint of the study was patient tolerability and toxicity, including CRS and ICANS grades
    .

    Study Results 1 Patient Characteristics The study enrolled 13 patients from December 2019 to the data cutoff date (November 2021), and 12 patients eventually received Tisagenlecleucel infusion
    .

    The median time from leukapheresis to infusion was 33 days (range: 27-37 days) in the 12 patients infused, and the median time from infusion to data cutoff was 12.
    2 months (range: 3.
    64-23.
    5 months)
    .

    Baseline patient characteristics showed a median age of 63 years (range: 34-81 years) (see Table 1 for details)
    .

    All patients had disease progression or treatment failure after HD-MTX treatment; 3 patients had prior autologous hematopoietic stem cell transplantation (ASCT), and 4 patients had prior radiotherapy
    .

    All patients had lesions measurable by MRI and/or cytology/flow cytometry (FCM) prior to infusion
    .

    Table 1: Patient Baseline Characteristics 2 Patient Safety All patients required bridging therapy, including steroids, for symptomatic disease and disease-related brain edema after leukapheresis and before initiation of LDC therapy
    .

    Four of these patients required continued use of steroids for symptomatic disease characterized by left-sided weakness (patient 002), lower extremity weakness (patient 009), worsening cranial nerve deficits (patient 011), and refractory headache (patient 015) )
    .

    Three of the four patients requiring continuous steroid use were able to reduce steroids to physiologic doses at month 1 and achieve remission at the first assessment
    .

    All patients developed low-grade CRS and/or ICANS (Table 2)
    .

    Of the 12 patients infused with Tisagenlecleucel, grade 1 CRS occurred in 7 patients with a median of 4 days after Tisagenlecleucel infusion and a duration of 2 days
    .

    No patients required tocilizumab or other therapy
    .

    ICANS occurred in 6 of 12 patients (50%), all of whom received at least one dose of dexamethasone; median time to onset was 5 days and median duration was 3 days
    .

    Grade 1 ICANNs were observed in 3 (25%) patients, mainly manifesting as mild confusion
    .

    Grade 2 ICANS occurred in 2 patients (16.
    7%), manifested by difficulty in word recall and decreased level of consciousness
    .

    Patient 002 developed grade 3 ICANS with worsening left-sided weakness
    .

    Table 2: The incidence of CRS and ICANS in patients 3 Patient efficacy Remissions were observed in 7/12 patients, including 6 complete remissions (CR) and 1 partial remission (PR) (Figure 1)
    .

    The median time from infusion to data cutoff was 12.
    2 months, with 7/12 patients alive and 3/12 patients without disease progression
    .

    The median time to best response for patients at data cutoff was 3.
    4 months
    .

    Cerebrospinal fluid (CSF) of all responders were negative for MYD88 by cytology, flow cytometry, IgH sequencing, and PCR; treatment response areas included large intraparenchymal masses and pia mater and CSF involvement
    .

    Figure 1: Evaluable patient efficacy and associated CRS/ICANS4 cell expansion and phenotype analysis after Tisagenlecleucel infusion.
    Tisagenlecleucel cell expansion in peripheral blood was observed and measured by flow cytometry; T levels accounted for 18.
    2% of CD45+ lymphocytes in peripheral blood (1226 CAR+ cells/μl) (Fig.
    2, patient 008)
    .

    Patients showed predominantly CD4+ CAR-T amplification with varying degrees of memory phenotypes (TSCM, TCM, TEMRA, TEM, and TN) (Figure 2)
    .

    Markers of T cell clearance, such as PD-1, TIM-3 and LAG-3, were identified during peak expansion
    .

    All patients enrolled in the study who continued to respond showed B-cell aplasia (defined as <1% B cells in peripheral blood by flow cytometry)
    .

    Figure 2: Patient Peripheral Blood CAR-T Expansion and Phenotyping 5CSF and Cytokine Analysis CAR-T cell transport into the CSF was observed in all peripheral blood-expanded patients
    .

    CAR transgenic RNA levels were higher in the CSF of patients with the best response in CR (Fig.
    3A)
    .

    According to the ratio of CAR expression to CD45+ cells, one patient showed relatively higher Tisagenlecucel levels in CSF than in peripheral blood (67.
    2% vs 18.
    2%, Figure 3B)
    .

    RNA analysis of CSF also found that patients whose best response was CR had increased expression of T-cell and macrophage gene pathways
    .

    Downregulation of genes associated with inflammatory cytokines (CCL4/CCL3), T-cell exhaustion (TOX), effector function (IKZF2), and a Jak family member (Tyk2) was also observed in patients who eventually achieved CR (Fig.
    3C)
    .

    Concomitant with CNS-transported CAR-T cells, we also noted a trend toward increased serum and CNS inflammatory cytokines 1 week after Tisagenlecleucel infusion compared with pre-infusion baseline (Fig.
    3D)
    .

    Figure 3: CSF and cytokine analysis results of pre/post-infusion samples Study Conclusions Overall, Tisagenlecleucel was well tolerated, with 42.
    9% of initial responders having sustained remission, suggesting that Tisagenlecleucel is safe and effective in adult patients with R/R PCNSL
    .

    References Matthew J Frigault , Jorg Dietrich , Kathleen ME Gallagher, et al.
    Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I/II clinical trial.
    Blood.
    2022 Feb 15; blood.
    2021014738.
    Review: Quinta typesetting: Wenting pokes "read the original text", we make progress together
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.